A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
NCT00952419
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after each injection. * To describe the safety of the candidate vaccines after each injection.
Gender:
ALL
Ages:
Between 6 months and 9 years
Trial Updated:
04/12/2016
Locations: Not set, Crestview Hills, Kentucky +2 locations
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Register for Updates
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
NCT00003715
Terminated
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/02/2015
Locations: James Graham Brown Cancer Center, Louisville, Kentucky
Conditions: Melanoma (Skin)
Register for Updates
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
NCT00257465
Completed
The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2015
Locations: University of Louisville, Louisville, Kentucky
Conditions: Melanoma
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
NCT01000311
Completed
This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
04/03/2014
Locations: 29 Kentucky Pediatric/Adult Research 201 South 5th Street, Bardstown, Kentucky +5 locations
Conditions: Meningococcal Disease
Register for Updates
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
NCT00006470
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: Central Baptist Hospital, Lexington, Kentucky +5 locations
Conditions: Lung Cancer
Register for Updates
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
NCT00806195
Completed
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
05/13/2013
Locations: 51 Kentucky Pediatric/Adult Research 201 S. 5th Street, Bardstown, Kentucky +6 locations
Conditions: Meningitis, Meningococcal Infection
Register for Updates
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958
Completed
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
01/17/2013
Locations: Not set, Bardstown, Kentucky +2 locations
Conditions: Vaccines, Pneumococcal
Register for Updates
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
NCT00772928
Completed
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjugate vaccine (Prevnar®). Primary Objective - Stage II: To compare the immune responses elicited by a 4th dose of Pentacel™ when given at different times from or concurrently with Prevnar®.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
01/30/2012
Locations: Not set, Bardstown, Kentucky +1 locations
Conditions: Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Register for Updates
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
NCT00094653
Completed
The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an obje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2011
Locations: Central Baptist Hospital, Lexington, Kentucky +3 locations
Conditions: Melanoma, Metastases
Register for Updates